ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo hopes to tame tough breast cancer
Disease control OngoingThis early-stage trial is testing a new drug called HRS8807, alone or combined with another drug (SHR6390), in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to check safety and find the best dose for future studies.…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New pill combo aims to outsmart resistant breast cancer
Disease control OngoingThis phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThis study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
Cancer DNA blood test study halted before it began
Disease control TerminatedThis study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
AI may predict breast cancer return better than current methods
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back in a different part of the body. Researchers will analyze tissue samples and health records from 2,200 women who were previously treated for ER-p…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated Jun 01, 2026 17:55 UTC